Announcement on Change of Sponsor Representative
Filed with SSE · · 2 pages · Chinese
Frontier Biotechnologies Inc. on 6ix
Earlier from Frontier Biotechnologies
- Announcement on Resolution of the 2024 Annual General Meeting
- Announcement on Signing the Supplementary Agreement and Passive Extension of Related Party Loans
- Announcement on Attending the Annual Collective Performance Briefing for Innovative Drug Companies on SSE STAR Market 2024 and Convening the Q1 2025 Performance Briefing
- Announcement on Preliminary Earnings Estimate for 2024
- Announcement on Voluntary Disclosure of the Notice of Acceptance for Registration and Marketing License of FB3002 Loxoprofen Sodium Patches Obtained for Drug Manufactured in China
Later from Frontier Biotechnologies
- Announcement on Reply to the Regulatory Inquiry Letter on Information Disclosure of 2024 Annual Report
- Announcement on Resolutions of the 3rd Meeting of the 4th Board of Supervisors
- Announcement on Changing Some Investment Projects Financed by Raised Funds
- Announcement on Repayment of Previously Temporarily Used Raised Funds for Working Capital and Continued Use of Partial Idle Raised Funds to Temporarily Supplement Working Capital
- Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025
Follow Frontier Biotechnologies into a list and get an email when it puts out news.
Follow Frontier Biotechnologies